A Strong Growth Profile Gives Boston Scientific Corp. (BSX) a Favorable Outlook

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can be downloaded here. The portfolio underperformed in the quarter due to stock selection. The composite returned 5.02%, net of fees, compared to 7.62% for the MSCI AC World Net Index. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Hardman Johnston Global Equity Strategy highlighted stocks such as Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) manufactures and markets medical devices that operate in the MedSurg and Cardiovascular segments. The one-month return of Boston Scientific Corporation (NYSE:BSX) was -4.78%, and its shares gained 5.56% of their value over the last 52 weeks. On December 24, 2025, Boston Scientific Corporation (NYSE:BSX) stock closed at $96.13 per share, with a market capitalization of $142.51 billion.

Hardman Johnston Global Equity Strategy stated the following regarding Boston Scientific Corporation (NYSE:BSX) in its third quarter 2025 investor letter:

"Within Health Care, Boston Scientific Corporation (NYSE:BSX) and Vertex Pharmaceuticals Inc. were the largest drivers of underperformance. The Trump administration announced a Section 232 tariff investigation into medical devices increasing macro uncertainty. Boston Scientific Corp. is well positioned to manage tariffs given their diverse supply chain and increased US manufacturing footprint post COVID. Boston also has strong pricing power and has been able to largely mitigate tariffs this far. Any outcome from the Section 232 investigation will be capped for countries that have existing trade deals (e.g. 15% tariff for European Union). The market has also seen a rotation within healthcare from medical devices to pharmaceuticals/biotech as the first deal was announced between Pfizer/Trump administration (late September 2025). Headwinds are easing in other areas of healthcare placing them "in favor" relative to medtech. We continue to view Boston Scientific favorably, supported by its diversified growth profile across cardiology, electrophysiology, endoscopy, and urology franchises. Farapulse, pulsed-field ablation technology, is practice changing for electrophysiologists and is expected to drive significant growth over upcoming years. At its recent Capital Markets Day, management introduced new long-term targets of 10% organic revenue growth, 50 bps of annual margin expansion, and double-digit EPS growth through 2028. Having exceeded targets from six consecutive investor days, management’s credibility suggests upside to these new goals."

Boston Scientific Corporation (NYSE:BSX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 102 hedge fund portfolios held Boston Scientific Corporation (NYSE:BSX) at the end of the third quarter, compared to 100 in the previous quarter. Boston Scientific Corporation (NYSE:BSX) announced that its consolidated revenue for the third quarter of 2025 reached $5.065 billion, indicating a 20.3% growth compared to Q3 2024.  While we acknowledge the potential of Boston Scientific Corporation (NYSE:BSX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Boston Scientific Corporation (NYSE:BSX) and shared Parnassus Core Equity Fund's views on the company. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.